Nexstim Reports Excellent Treatment Outcomes of Over 400

Press launch, Helsinki, 11 October 2022 at 9 AM (EEST)

Nexstim Reports Excellent Treatment Outcomes of Over 400 MDD Patients in Patient Registry

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) studies medical outcomes of the 403 sufferers who’ve accomplished Nexstim SmartFocus® rTMS (repetitive Transcranial Magnetic Stimulation) therapy with Nexstim NBT® system for main depressive dysfunction (MDD). Nexstim NBT® system is indicated for the therapy of MDD in grownup sufferers who’ve failed to realize passable enchancment from prior antidepressant medicine within the present episode.

Treatment outcomes of these 403 sufferers had been glorious: 49.6% had been in remission at finish of therapy and 76.2% had obtained a medical response.

These outcomes are clearly greater than what’s normally reported for MDD: In a well-conducted multisite examine, remission charges had been 26.5-28.7% and the patient-reported response charges had been 41.5- 56.4%¹. The patient-reported remission and response charges are additionally greater than these reported in a big >3800 affected person collection for sufferers finishing medical rTMS therapy (remission 29.7-36.2%, response 62.7-70.4%)².

The common affected person reported Patient Health Questionnaire (PHQ-9) despair symptom severity rating within the Nexstim registry was 21.0 earlier than therapy and decreased to six.6 by finish of therapy. In the >3800 affected person collection the common PHQ-9 rating earlier than therapy was reported to be 19.8 and to have decreased to 11.1 by finish of therapy². The vary of PHQ-9 is from 0 to 27 with greater scores indicating extra extreme signs. The scores correspond to illness severity as follows: 0-4 = none to minimal despair, 5-9 = delicate despair, 10-14 = reasonable despair, 15-19 = reasonably extreme despair, 20-27 = extreme despair.

The medical outcomes of majority of the sufferers handled with SmartFocus® rTMS within the United States are being collected in a registry — the nameless info is supplied by taking part medical websites utilizing Nexstim’s SmartFocus® know-how.

According to the registry, the common normal impression of receiving SmartFocus® rTMS therapy reported by the sufferers having accomplished the therapy was very optimistic with a imply rating of 9.29 on a scale from 0 to 10 (10 = very best).

Mikko Karvinen, CEO of Nexstim, mentioned: “Since our last report on the Patient Registry earlier in 2022 the number of patients has continued to increase and reinforce the existing treatment outcome results. We are proud to report such excellent remission and response rates, demonstrating how our innovations create a possibility for a better life for depression patients.”

^{1) Carpenter L. et al. Transcranial magnetic stimulation (TMS) for main despair: a multisite, naturalistic, observational examine of acute therapy outcomes in medical follow. Depress Anxiety. 2012 Jul;29(7):587-96. Epub 2012 Jun 11.
2) Sackeim, H. et al. Clinical outcomes in a big registry of sufferers with main depressive dysfunction handled with Transcranial Magnetic Stimulation. Journal of Affective Disorders 277 (2020) 65–74.}

Further info is obtainable on the web site www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
[email protected]

About Nexstim Plc

Nexstim is a Finnish, globally working growth-oriented medical know-how firm. Our mission is to allow customized and efficient diagnostics and therapies for difficult mind ailments and issues.

Nexstim has developed a world-leading non-invasive mind stimulation know-how for navigated transcranial magnetic stimulation (nTMS) with extremely refined 3D navigation offering correct and customized concentrating on of the TMS to the precise space of the mind.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the one FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the mind.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for advertising and industrial distribution for the therapy of main depressive dysfunction (MDD) within the United States. In Europe, the NBT® system is CE marked for the therapy of main despair and power neuropathic ache.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For extra info, please go to www.nexstim.com

• Nexstim_Plc_Press_release_Patient_Registry_11102022_FINAL